Physician profile
Gary D Carr
NPI 1245264183
$1,729.38
in general payments reported to CMS, 2019-2025
28 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $223 · 2021: $216 · 2022: $335 · 2023: $306 · 2024: $258 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $320.96 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $253.74 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $144.26 | 2019-2025 | |
| Abbvie INC. | $131.84 | 2023-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $102.89 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.76 | 2021-2024 | Xifaxan |
| Abbott Laboratories | $82.53 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.08 | 2023-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $72.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $52.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.43 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.34 | 2022 | |
| Avanir Pharmaceuticals, INC. | $34.26 | 2021-2022 | |
| Amarin Pharma, INC. | $31.65 | 2020-2021 | |
| Medtronic, INC. | $29.91 | 2021-2023 | Minimed 770g |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28.68 | 2023 | Injectafer |
| Pfizer INC. | $28.48 | 2020 | |
| Phathom Pharmaceuticals, INC. | $22.60 | 2024 | Voquezna |
| Astellas Pharma US INC | $21.11 | 2020 | |
| Ironshore Pharmaceuticals INC. | $16.46 | 2024 | |
| Nestle Healthcare Nutrition INC. | $15.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.45 | 2021 | |
| Merck Sharp & Dohme LLC | $13.70 | 2020 | |
| Dexcom, INC. | $13.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.89 | 2023 | Trintellix |
| Eisai INC. | $12.85 | 2021 | |
| Mylan Specialty L.P. | $11.90 | 2021 | |
| Amgen INC. | $11.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.